Literature DB >> 22462650

Role of comorbidities in outcome prediction after status epilepticus.

Vincent Alvarez1, Jean-Marie Januel, Bernard Burnand, Andrea O Rossetti.   

Abstract

Status epilepticus (SE) is associated with significant mortality and morbidity. A reliable prognosis may help better manage medical resources and treatment strategies. We examined the role of preexisting comorbidities on the outcome of patients with SE, an aspect that has received little attention to date. We prospectively studied incident SE episodes in 280 adults occurring over 55 months in our tertiary care hospital, excluding patients with postanoxic encephalopathy. Different models predicting mortality and return to clinical baseline at hospital discharge were compared, which included demographics, SE etiology, a validated clinical Status Epilepticus Severity Score (STESS), and comorbidities (assessed with the Charlson Comorbidity Index) as independent variables. The overall short-term mortality was 14%, and only half of patients returned to their clinical baseline. On bivariate analyses, age, STESS, potentially fatal etiologies, and number of preexisting comorbidities were all significant predictors of both mortality and return to clinical baseline. As compared with the simplest predictive model (including demographics and deadly etiology), adding SE severity and comorbidities resulted in an improved predictive performance (C statistics 0.84 vs. 0.77 for mortality, and 0.86 vs. 0.82. for return to clinical baseline); comorbidities, however, were not independently related to outcome. Considering comorbidities and clinical presentation, in addition to age and etiology, slightly improves the prediction of SE outcome with respect to both survival and functional status. This analysis also emphasizes the robust predictive role of etiology and age. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2012        PMID: 22462650     DOI: 10.1111/j.1528-1167.2012.03451.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

1.  Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison.

Authors:  Vincent Alvarez; Jong Woo Lee; Frank W Drislane; M Brandon Westover; Jan Novy; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Epilepsia       Date:  2015-07-03       Impact factor: 5.864

2.  Treatment deviating from guidelines does not influence status epilepticus prognosis.

Authors:  Andrea O Rossetti; Vincent Alvarez; Jean-Marie Januel; Bernard Burnand
Journal:  J Neurol       Date:  2012-08-17       Impact factor: 4.849

3.  Status epilepticus of inflammatory etiology: a cohort study.

Authors:  Marianna Spatola; Jan Novy; Renaud Du Pasquier; Josep Dalmau; Andrea O Rossetti
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

4.  Epidemiology-based mortality score in status epilepticus (EMSE).

Authors:  M Leitinger; Y Höller; G Kalss; A Rohracher; H F Novak; J Höfler; J Dobesberger; G Kuchukhidze; E Trinka
Journal:  Neurocrit Care       Date:  2015-04       Impact factor: 3.210

5.  Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus.

Authors:  Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

6.  Institutional Factors Contribute to Variation in Intubation Rates in Status Epilepticus.

Authors:  Elan L Guterman; James F Burke; S Andrew Josephson; John P Betjemann
Journal:  Neurohospitalist       Date:  2018-12-18

7.  Efficacy and safety of lacosamide in the treatment of status epilepticus in a patient with comorbidities.

Authors:  Alfredo Paolo Mascolo; Federico Marrama; Nicola Biagio Mercuri; Fabio Placidi
Journal:  Acta Biomed       Date:  2021-04-30

8.  Factors associated with poor discharge status in patients with status epilepticus at Khon Kaen Hospital.

Authors:  Piyawan Chiewthanakul; Parinya Noppaklao; Kittisak Sawanyawisuth; Somsak Tiamkao
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-20       Impact factor: 2.570

Review 9.  A Theoretical Paradigm for Evaluating Risk-Benefit of Status Epilepticus Treatment.

Authors:  Edilberto Amorim; Chris M McGraw; M Brandon Westover
Journal:  J Clin Neurophysiol       Date:  2020-09       Impact factor: 2.590

Review 10.  Markers in Status Epilepticus Prognosis.

Authors:  Ayham Alkhachroum; Caroline A Der-Nigoghossian; Clio Rubinos; Jan Claassen
Journal:  J Clin Neurophysiol       Date:  2020-09       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.